Psychedelics are redefining the landscape of psychiatric care, offering promising interventions for conditions like depression, PTSD, and addiction. This session will provide an in-depth exploration of emerging research on compounds such as ibogaine, 5-MeO-DMT, and DMT, as well as data from leading clinical trials. Attendees will gain practical insights into the expanding therapeutic potential of psychedelics beyond major depressive disorder, including their applications in treating substance use disorders and generalized anxiety. The session will also address the growing divide between medical, personal, and decriminalized uses of psychedelics, equipping clinicians with the knowledge to navigate this evolving field responsibly and effectively.